pravastatina aurovitas 40 mg comprimido - Resultados da pesquisa

União Europeia - eslovaco - EMA (European Medicines Agency)

tabrecta

novartis europharm limited - capmatinib dihydrochloride monohydrate - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

União Europeia - eslovaco - EMA (European Medicines Agency)

lupkynis

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresíva - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

União Europeia - eslovaco - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomide - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

União Europeia - eslovaco - EMA (European Medicines Agency)

teriflunomide accord

accord healthcare s.l.u. - teriflunomide - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresívami, selektívne imunosupresívami - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).